Biliary Tract Cancers (BTCs) Market GRÖSSEN- UND MARKTANTEILSANALYSE - WACHSTUMSTRENDS UND PROGNOSEN (2024 - 2031)
Biliary Tract Cancers (BTCs) Market is segmented By Treatment (Chemotherapy (Platinum-based Agents, Fluoropyrimidines, Gemcitabine), Targeted Therapy (Tyrosine Kinase Inhibitors, FGFR Inhibitors), Immunotherapy (PD-1/PD-L1 Inhibitors, Radiation Therapy)), By Cancer Type (Intrahepatic Bile Duct Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Biliary Tract Cancers (BTCs) Market Size
Marktgröße in USD Bn
CAGR5.5%
| Studienzeitraum | 2024 - 2031 |
| Basisjahr der Schätzung | 2023 |
| CAGR | 5.5% |
| Marktkonzentration | Medium |
| Hauptakteure | Roche Holding AG, Merck & Co., Inc., AstraZeneca plc, Bristol Myers Squibb Company, Novartis AG and Among Others. |
please let us know !
Biliary Tract Cancers (BTCs) Market Analysis
The biliary tract cancers (BTCs) market is estimated to be valued at USD 0.822 billion in 2024 and is expected to reach USD 1.196 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031. The increasing prevalence of biliary tract cancers such as gallbladder and bile duct cancers due to changing lifestyle patterns and rising geriatric population is driving the growth of this market.